Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study)

International Journal of Cancer

Volumn 138, Issue 4, 2016, Pages 992-1002

  Luttmer, Roosmarijn ^a   De Strooper, Lise M A ^a   Berkhof, Johannes ^a   Snijders, Peter J F ^a   Dijkstra, Maaike G ^a   Uijterwaal, Margot H ^b   Steenbergen, Renske D M ^a   Van Kemenade, Folkert J ^c   Rozendaal, Lawrence ^a   Helmerhorst, Theo J M ^c   Verheijen, Rene H M ^d   Ter Harmsel, W Abraham ^e   Van Baal, W Marchien ^b   Graziosi, Peppino G C M ^f   Quint, Wim G V ^g   Heideman, Daniëlle A M ^a   Meijer, Chris J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Flevo Hospital   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e Department of Dermatology   (Netherlands)

^f ST ANTONIUS HOSPITAL   (Netherlands)

^g DDL DIAGNOSTIC LABORATORY   (Netherlands)

Author keywords

cervical cancer; cervical intraepithelial neoplasia; cervical scrapes; DNA methylation; human papillomavirus; qMSP

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER DIAGNOSIS; CERVICAL SCRAPE; COHORT ANALYSIS; COLPOSCOPY; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA METHYLATION; FAM19A4 GENE; FEMALE; GENE; GENOTYPE; GYNECOLOGICAL EXAMINATION; GYNECOLOGY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NONHUMAN; OBSERVATIONAL STUDY; OUTPATIENT; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; GENETICS; MIDDLE AGED; MULTICENTER STUDY; ODDS RATIO; PAPILLOMAVIRUS INFECTION; RISK FACTOR; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY;

CHEMOKINE; CYTOKINE; TAFA4 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; BIOMARKERS, TUMOR; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHEMOKINES; COHORT STUDIES; CYTOKINES; DNA METHYLATION; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; ODDS RATIO; OUTPATIENTS; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84954397254     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29824     Document Type: Article

References (50)

1. Steenbergen RDM, Snijders PJF, Heideman DAM, et al., Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 2014; 14: 395-405.
2. Walboomers JM, Jacobs MV, Manos MM, et al., Human papillomavirus is a necessary cause of invasive cervical cancer world-wide. J Pathol 1999; 189: 12-9.
3. Naucler P, Ryd W, Törnberg S, et al., Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-97.
4. Ronco G, Dillner J, Elfström KM, et al., Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2013; 39: 1-9.
5. Dillner J., Primary human papillomavirus testing in organized cervical screening. Curr Opin Obstet Gynecol 2013; 25: 11-6.
6. Rijkaart DC, Berkhof J, van Kemenade FJ, et al., Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012; 130: 602-10.
7. Burger EA, Kornør H, Klemp M, et al., HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol 2011; 120: 430-8.
8. Luttmer R, Berkhof J, Dijkstra MG, et al., Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women. J Clin Virol 2015; 67: 59-66.
9. Uijterwaal MH, Witte BI, Van Kemenade FJ, et al., Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study. Br J Cancer 2014; 110: 1579-86.
10. Carozzi F, Gillio-Tos A, Confortini M, et al., Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2013; 14: 168-76.
11. Castle PE, Stoler MH, Wright TC, et al., Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011; 12: 880-90.
12. Cox JT, Castle PE, Behrens CM, et al., Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol 2013; 208: 184.e1-1.
13. Dijkstra M, van Niekerk D, Rijkaart D, et al., Primary hrHPV DNA testing in cervical cancer screening: how to manage screen positive women? A POBASCAM trial sub study. Cancer Epidemiol Biomarkers Prev 2014; 23: 55-63.
14. Tornesello ML, Buonaguro L, Giorgi-Rossi P, et al., Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer. Biomed Res Int 2013; 2013: 519619.
15. Eijsink JJH, Lendvai Á, Deregowski V, et al., A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer 2012; 130: 1861-9.
16. Hesselink AT, Heideman DAM, Steenbergen RDM, et al., Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res 2011; 17: 2459-65.
17. Hesselink AT, Heideman DAM, Steenbergen RDM, et al., Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy. Int J Cancer 2014; 135: 880-6.
18. Verhoef VMJ, Bosgraaf RP, van Kemenade FJ, et al., Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol 2014; 15: 315-22.
19. Eijsink JJH, Yang N, Lendvai A, et al., Detection of cervical neoplasia by DNA methylation analysis in cervico-vaginal lavages, a feasibility study. Gynecol Oncol 2011; 120: 280-3.
20. Lin H, Chen T-C, Chang T-C, et al., Methylated ZNF582 gene as a marker for triage of women with Pap smear reporting low-grade squamous intraepithelial lesions-A Taiwanese gynecologic oncology group (TGOG) study. Gynecol Oncol 2014; 135: 64-8.
21. De Strooper LMA, van Zummeren M, Steenbergen RDM, et al., CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer. J Clin Pathol 2014; 67: 1067-71.
22. Steenbergen RDM, Ongenaert M, Snellenberg S, et al., Methylation-specific digital karyotyping of HPV16E6E7 expressing human keratinocytes identifies novel methylation events in cervical carcinogenesis. J Pathol 2013; 231: 53-62.
23. De Strooper LMA, Meijer CJLM, Berkhof J, et al., Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions. Cancer Prev Res 2014; 7: 1251-7.
24. Bierkens M, Wilting SM, van Wieringen WN, et al., Chromosomal profiles of high-grade cervical intraepithelial neoplasia relate to duration of preceding high-risk human papillomavirus infection. Int J Cancer 2012; 131: E579-85.
25. Hanselaar A., Criteria for organized cervical screening programs. Special emphasis on The Netherlands program. Acta Cytol 2002; 46: 619-29.
26. Schmitt M, Bravo IG, Snijders PJF, et al., Bead-based multiplex genotyping of human papillomaviruses bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006; 44: 504-12.
27. Overmeer RM, Henken FE, Snijders PJF, et al., Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J Pathol 2008; 1: 388-97.
28. Overmeer RM, Henken FE, Bierkens M, et al., Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. J Pathol 2009; 219: 327-36.
29. Trimble CL, Piantadosi S, Gravitt P, et al., Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 2005; 11: 4717-23.
30. Ostör AG., Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12: 186-92.
31. Tang N-S, Tang M-L, Chan ISF., On tests of equivalence via non-unity relative risk for matched-pair design. Stat Med 2003; 22: 1217-33.
32. Meijer CJLM, Berkhof J, Castle PE, et al., Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009; 124: 516-20.
33. Ho GY, Bierman R, Beardsley L, et al., Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423-8.
34. Insinga RP, Perez G, Wheeler CM, et al., Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev 2010; 19: 1585-94.
35. Bierkens M, Hesselink AT, Meijer CJLM, et al., Promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J Cancer 2013; 133: 1293-9.
36. De Strooper LMA, Hesselink AT, Berkhof J, et al., Combined CADM1/MAL methylation and cytology testing for colposcopy triage of high-risk HPV-positive women. Cancer Epidemiol Biomarkers Prev 2014; 23: 1933-7.
37. Louvanto K, Chevarie-Davis M, Ramanakumar AV, et al., HPV testing with cytology triage for cervical cancer screening in routine practice. Am J Obstet Gynecol 2014; 210: 474.e1-7.
38. Benoy IH, Vanden Broeck D, Ruymbeke MJ, et al., Prior knowledge of HPV status improves detection of CIN2+ by cytology screening. Am J Obstet Gynecol 2011; 205: 569.e1-7.
39. Cuzick J, Clavel C, Petry K-U, et al., Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-101.
40. Wentzensen N, Sherman ME, Schiffman M, et al., Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol 2009; 112: 293-9.
41. Overmeer RM, Louwers JA, Meijer CJLM, et al., Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Int J Cancer 2011; 129: 2218-25.
42. Hansel A, Steinbach D, Greinke C, et al., A promising DNA methylation signature for the triage of high-risk human papillomavirus DNA-positive women. PLoS One 2014; 9: e91905.
43. Winer RL, Lee S-K, Hughes JP, et al., Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157: 218-26.
44. Jaisamrarn U, Castellsagué X, Garland SM, et al., Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS One 2013; 8: e79260.
45. Benard VB, Watson M, Castle PE, et al., Cervical carcinoma rates among young females in the United States. Obstet Gynecol 2012; 120: 1117-23.
46. Massad LS, Einstein MH, Huh WK, et al., 2012 Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2013; 17: 1-27.
47. Arbyn M, Kyrgiou M, Simoens C, et al., Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008; 337: a1284.
48. Conner SN, Frey HA, Cahill AG, et al., Loop electrosurgical excision procedure and risk of preterm birth. Obstet Gynecol 2014; 123: 752-61.
49. Abraham J, Stenger M., Cobas HPV test for first-line screening for cervical cancer. J Commun Support Oncol 2014; 12: 156-7.
50. Wright TC, Stoler MH, Behrens CM, et al., Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol 2015; 136: 189-97.